LIM
MACK

Lagoda Investment Management’s Merrimack Pharmaceuticals, Inc. MACK Stock Holding History

Lagoda Investment Management’s Portfolio MACK Stock Details MACK Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2017
Q2 		– Sell
-98,575
Closed -$2.39M – 40
2017
Q1 		$2.39M Sell
98,575
-94,938
-49% -$2.38M 0.93% 17
2016
Q4 		$6.21M Sell
193,513
-44,263
-19% -$1.89M 2.13% 15
2016
Q3 		$11.9M Sell
237,776
-47,447
-17% -$1.97M 3.57% 15
2016
Q2 		$12.1M Sell
285,223
-10,615
-4% -$578K 4.51% 10
2016
Q1 		$19.5M Buy
295,838
+14,708
+5% +$768K 6.38% 8
2015
Q4 		$17.5M Sell
281,130
-18,516
-6% -$1.3M 4.63% 10
2015
Q3 		$20.1M Buy
299,646
+32,718
+12% +$2.67M 5.86% 7
2015
Q2 		$26M Buy
266,928
+21,387
+9% +$2.04M 6.81% 5
2015
Q1 		$23M Buy
245,541
+47,198
+24% +$4.02M 6.14% 6
2014
Q4 		$17.6M Buy
+198,343
New +$14.4M 4.71% 12

Other funds holding MACK

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
TCIM
TIAA CREF Investment Management New York $141B AUM 14.18% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Northern Trust
Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
CC
Cannell & Co New York $3.15B AUM 30.62% 1-Year Est. Return

Lagoda Investment Management's MACK Position: Q2 2017 in Review

Lagoda Investment Management sold out of Merrimack Pharmaceuticals, Inc. (MACK) in Q2 2017, closing a stake of 98,575 shares — an estimated $2.39M sold.

Lagoda Investment Management first reported a position in MACK in Q4 2014 and held it in 10 quarters. The position peaked at $26M in Q2 2015. 119 funds tracked by Wall St. Rank hold MACK as of Q2 2017.

  • Lagoda Investment Management reported no remaining Merrimack Pharmaceuticals, Inc. position as of Q2 2017 after selling out during the quarter.
  • Lagoda Investment Management sold 98,575 Merrimack Pharmaceuticals, Inc. shares in Q2 2017, an estimated $2.39M.
  • Lagoda Investment Management first reported a position in Merrimack Pharmaceuticals, Inc. in Q4 2014 and held it in 10 quarters.
  • Lagoda Investment Management's Merrimack Pharmaceuticals, Inc. position peaked at $26M in Q2 2015.
  • 119 funds tracked by Wall St. Rank held Merrimack Pharmaceuticals, Inc. as of Q2 2017.

Based on Lagoda Investment Management's 13F filing for Q2 2017, filed 14 Aug 2017.